Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | NR4A2 | P43354 | 4/20 | 0.55 |
| ▸ | ESR1 | P03372 | 2/20 | 0.54 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.54 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.53 |
| ▸ | THRA | P10827 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.50 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6623073 | 0.89 | KMT2A (0.69) | KMT2ANR4A2ESR1PLA2G4BTHRA | |
| Hydrochloric Acid SCHEMBL8702528 | 0.88 | KMT2A (0.68) | KMT2ANR4A2ESR1PLA2G4BTHRA | |
| SCHEMBL4299737 | 0.84 | KMT2A (0.70) | KMT2ANR4A2ESR1PLA2G4BNR1H4 | |
| Hydrochloric Acid SCHEMBL8705220 | 0.84 | ESR1 (0.66) | KMT2AESR1PLA2G4BNR1H4THRA | |
| SCHEMBL9803295 | 0.84 | KMT2A (0.80) | KMT2ANR4A2PLA2G4BNR1H4POLB | |
| SCHEMBL30167982 | 0.84 | KMT2A (0.80) | KMT2ANR4A2PLA2G4BNR1H4POLB | |
| SCHEMBL10787479 | 0.84 | KMT2A (0.80) | KMT2ANR4A2PLA2G4BNR1H4POLB | |
| SCHEMBL4509654 | 0.82 | KMT2A (0.77) | KMT2ANR4A2PLA2G4BNR1H4 | |
| SCHEMBL609434 | 0.81 | KMT2A (1.00) | KMT2ANR4A2PLA2G4BNR1H4ALDH1A1 | |
| SCHEMBL4511317 | 0.81 | DRD2 (0.64) | PLA2G4BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9120819-B2 | FGF-receptor agonist dimeric compounds | SANOFI (FR) | 2015-09-01 | — | — | US | disclosed |
| US-20090069368-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | SANOFI-AVENTIS (FR) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069368-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | FGF2, FGFR1, FGF1 | KMT2A 3395/4885NR4A2 264/4885ESR1 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.